OZEMPIC (Semaglutide) Detailed Presentation | CDE Exam Tips

Welcome to the channel!
In this video we cover the topic of the diabetes medication Ozempic (Semaglutide)

Ozempic is a diabetes medication for patients with Type 2 diabetes and is given by subcutaneous injection once-weekly.
The active ingredient/chemical in Ozempic is called Semaglutide which is a GLP-1 Receptor Agonist. This medication helps to lower BG levels, A1C and also helps in weight loss.

In this presentation we will cover:
-What is Semaglutide?
-What is GLP as an incretin hormone?
-Semaglutide Mechanism
-Indications for use
-How is it supplied?
-Storage
-Administration and Dosing and Dosing Considerations
-Missed dose
-Common Side effects and Managing Nausea
-Contraindications
-Gallstone and Pancreatitis
-Precautions
-Effect on Weight Loss

TIME STAMPS:
00:00 - INTRO
00:17 – Topics covered
00:38 - What is semaglutide?
00:52 - What is GLP?
02:00 - Semaglutide Mechanism
03:54 - Indications for use
04:53 - How is it supplied?
06:30 - Storage
07:03 - Administration
08:07 - Dosing
09:25 - Dosing Considerations
11:28 - Missed dose
12:18 - Common Side effects and Managing Nausea
13:55 - Contraindications
14:34 - Gallstone and Pancreatitis
17:17 - Precautions
18:01 - Effect on Weight Loss
20:56 - Summary


If you found this video helpful please give it a LIKE and SUBSCRIBE FOR MORE VIDEOS LIKE THIS.

NEED MORE PRACTICE MCQs to prepare for the CDE Exam? Check out this book: CANADIAN CERTIFIED DIABETES EDUCATOR EXAM PRACTICE MCQs
Available on AMAZON, CLICK HERE: https://amzn.to/2WsNUa0

Follow us on social media for tips, practice questions and updates:
FACEBOOK.   / cdeexamtips  

TWITTER:
@CDEexamtips

THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND DOES NOT REPLACE PROFESSIONAL ADVICE
ALWAYS SEEK ADVICE FROM YOUR HEALTHCARE PROVIDER

References:
Lipscombe L, Butalia S, Dasgupta K, et al. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Can J Diabetes 2020; 44:575-591. https://guidelines.diabetes.ca/CDACPG...

Ozempic website:
https://www.novomedlink.com/diabetes/...

Ozempic monograph:
https://www.novonordisk.ca/content/da...

https://www.accessdata.fda.gov/drugsa...

Gallbladder, Biliary Health and Hormones
Ozempic, Saxenda or Victoza have been linked to gallbladder or biliary diseases, especially when used long term.
https://www.whitelotusclinic.ca/gallb...

REFERENCES ABOUT CAUSES OF GALLSTONE FORMATION:
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. Erratum in: Front Endocrinol (Lausanne). 2021 Nov 10;12:786732. https://www.ncbi.nlm.nih.gov/pmc/arti...

EXENATIDE AND ALBIGLUTIDE
Keller J, Trautmann ME, Haber H, Tham LS, Hunt T, Mace K, et al.. Effect of Exenatide on Cholecystokinin-Induced Gallbladder Emptying in Fasting Healthy Subjects. Regul Pept (2012) 179:77–83.

Shaddinger BC, Young MA, Billiard J, Collins DA, Hussaini A, Nino A. Effect of Albiglutide on Cholecystokinin-Induced Gallbladder Emptying in Healthy Individuals: A Randomized Crossover Stud. J Clin Pharmacol (2017) 57:1322–9.

LIRAGLUTIDE
Nexøe-Larsen CC, Sørensen PH, Hausner H, Agersnap M, Baekdal M, Brønden A, et al.. Effects of Liraglutide on Gallbladder Emptying: A Randomized, Placebo-Controlled Trial in Adults With Overweight or Obesity. Diabetes Obes Metab (2018) 20:2557–64.

References for weight regain after medications discontinuation:
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252.
https://dom-pubs.onlinelibrary.wiley....

Mikhail N. Kosiborod, Meena Bhatta, Melanie Davies, John E. Deanfield, W. Timothy Garvey, Usman Khalid, Robert Kushner, Domenica M. Rubino, Niels Zeuthen, Subodh Verma, Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses, Diabetes, Obesity and Metabolism, 10.1111/dom.14890, 25, 2, (468-478), (2022). https://dom-pubs.onlinelibrary.wiley....

References for Importance of Weight Loss in Diabetes:
Wharton S, Pedersen P, Lau D et al. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Ch.17 Weight Management in Diabetes. Can J Diabetes 2018;42(Suppl 1):S124-S129.
http://guidelines.diabetes.ca/docs/cp...